维普期刊资源整合服务平台（V6.5）

76篇 您的检索式：作者名="COLEY HM"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study 显示文摘	Coley HM Sargent JM Williamson CJ	2002	A nticancer Res2002，22，1：	2
2	Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein 显示文摘	Thomas H Coley HM	2003	Cancer Control2003，10，2：	1
3	Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein 显示文摘	Thomas H Coley HM	2003	Cancer Control2003，10，2：	1
4	,Overcoming multidrug resistance in cancer:an update on the clinical strategy of inhibiting p-glycoprotein显示文摘	Coley HM	2003	Iancer Control2003，10，2：	1
5	Receptor tyrosine kinase(RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents 显示文摘	Coley HM Shotton CF Ajose-Adeogun A	2006	Biochem Pharmacol2006，72，8：	1
6	The context and potential of epigenetics in oneology显示文摘	Lopez J Percharde M Coley HM	2009	Br J Cancer2009，100，4：	1
7	Overcoming multidrug resistance in cancer:an update on the clinical strategy of inhibiting p-glycoprotien显示文摘	Thomas H Coley HM	2003	Cancer Control2003，10，2：	1
8	Seliciclib (CYC202; r-roscovitine) in combination with cytotoxic agents in human uterine sarcoma cell lines 显示文摘	Coley HM Shotton CF Thomas H	2007	Anticancer Res2007，27，1：	1
9	Overcoming multidrug resistance in cancer:an update on the clinical strategy of inhibiting p-glycoprotien 显示文摘	Thomas H Coley HM	2003	Cancer Control2003，10，2：	1
10	The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines 显示文摘	Coley HM Shotton CF Kokkinos MI	2007	Gynecol Oncol2007，105，2：	1
11	Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures:a feasibility study 显示文摘	COLEY HM SARGENT JM WILLIAMSON CJ	2002	Anticancer Res2002，22，1：	1
12	Overcoming muhidrug resistance in canc- er: an update on the clinical strategy of inhibiting p -glycoprotein 显示文摘	Thomas H Coley HM	2003	Cancer Control2003，10，2：	1
13	Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: a feasibility study显示文摘	COLEY HM SARGENT JM WILLIAMSON C J	2002	AnticancerRes2002，22，1：	1
14	Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents 显示文摘	Coley HM Shotton CF Ajose-Adeogun A	2006	Biochem Pharmacol2006，72，：	1
15	Overcoming multidrug resistance in cancer:an update on the clinical strategy of inhibiting p-glycoprotein 显示文摘	Coley HM	2003	Cancer Control2003，10，2：	1
16	Cellular glutathione content,in vitro chemoresponse,and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer显示文摘	Lewandowicz GM Britt P Elgie AW Williamson CJ Coley HM Hall AG	2002	Gynecol Oncol2002，85，：	1
17	Overcoming muhidrug resistance in cancer:an update on the clinical strategy of inhibiting p-glycoprotein显示文摘	Coley HM	2003	Cancer Control2003，10，2：	1
18	Overcoming muhidrug resistance in cancer; an update on the clinical strategy of inhibiting P-glycopmtein显示文摘	Thomas H Coley HM	2003	Cancer Control2003，10，3：	1
19	Overcoming multidrug resistance in canc- er : An update on the clinical strategy of inhibiting p - glycoprotein 显示文摘	Thomas H Coley HM	2003	Can Contr2003，10，2：	1
20	Mechanisms and strategies to overcome che-motherapy resistance in metastatic breast cancer显示文摘	Coley HM		0，，04：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示